stockrow
Friday 6 November 2026
Export TELO’s income statement to Excel — free account
Telomir Pharmaceuticals, Inc.
TELO Healthcare Biotechnology
- EPS
- −364.7%
- Free cash flow
- −45.3%
Quarter to June 2026, against a year earlier
0.73
0.05
−6.41%
Follow TELO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (1) | (13) | (17) | (10) | (6) | +130.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (1) | (13) | (17) | (10) | (6) | +130.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (0.03) | (0.48) | (0.56) | (0.33) | (0.91) | +118.1% | ||||||
| Cash flow | — | — | — | — | — | — | (0.02) | (0.14) | (0.17) | (0.12) | (0.08) | +88.1% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (0.02) | (0.14) | (0.17) | (0.12) | (0.08) | +88.1% | ||||||
| Book value | — | — | — | — | — | — | (0.03) | 0.13 | 0.02 | 0.19 | 0.08 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 27 | 27 | 30 | 32 | 40 | +5.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 0 | (4) | (5) | (4) | (5) | +98.9% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | 0 | (4) | (5) | (4) | (5) | +98.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (1) | (1) | 1 | 6 | 5 | n/m | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (1) | (7) | (5) | +1,633.0% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (1) | 3 | 1 | 6 | 5 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (542.12) | (542.25) | (240.34) | (1,678.31) | (240.3) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | (69.64) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (1,045.38) | (810.19) | (317.65) | (1,885.50) | (317.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 9 | 6 | 2 | — | (30.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Telomir Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics, Inc. | $59.4M | 7.4× | — (loss-making) | −95.61% (below 0%: shrinking) | n/m | +69.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CRDF Cardiff Oncology, Inc. | $58.8M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| GOSS Gossamer Bio, Inc. | $57.6M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $57.5M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | |
| XBIT XBiotech Inc. | $57.0M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLNN Clene Inc. | $56.4M | — (loss-making) | — (loss-making) | +273.33% (above 0%: growing) | n/m | −16.61% (below 0%: shrinking) | 71.43% | (11,333.93%) | Compare |
| XLO Xilio Therapeutics, Inc. | $55.9M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLD Boundless Bio, Inc. | $54.8M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $56.7M | — | — | −19.59% | — | −21.42% | 100.00% | (9.34%) |
Pay and ownership Proxy statement filed 28 July 2026
Ownership
Directors and executive officers, together
16.36%
Brian McNulty
26.93%
Erez Aminov
16.10%
MIRA Pharmaceuticals, Inc.
5.12%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement